But when a dividend yield reaches ultrahigh levels, investors can feel a heightened level of uncertainty. Wondering if Pfizer ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

The company’s CEO said he’s had “productive discussions” with Trump administration officials on a recently launched trade ...

Like his Big Pharma peers, Pfizer (PFE) CEO Albert Bourla is waiting for the US government to finalize its decision on ...

Nevertheless, Albert Bourla has been lobbying the U.S. government—as high as President Donald Trump himself—to skip the ...

Pfizer CEO Albert Bourla on Tuesday said uncertainty around President Donald Trump’s planned pharmaceutical tariffs is deterring the company from further investing in U.S. manufacturing and ...

Goldman Sachs keeps Neutral on Pfizer, citing unclear product growth plans and focus on M&A amid changing market valuations ...

For years, Pfizer was the only drugmaker with treatments for the disease, called ATTR-CM, but BridgeBio’s CEO said in an ...

Pfizer is raising the bar for its sweeping cost-savings drive yet again, this time cranking up the total target to $7.7 ...

Pfizer CEO says tariffs are discouraging the company from investing in the US. Pfizer's full-year guidance does not factor in ...

Pfizer Inc. is cutting at least another $1.2 billion from its spending while the company searches for its next big hit after ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Pfizer will maintain its 2025 financial forecasts ...